Journal
EUROPEAN JOURNAL OF CANCER
Volume 50, Issue 15, Pages 2532-2543Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2014.07.013
Keywords
Pharmacogenetics; Gene polymorphisms; Cancer treatments; Cancer clinical trials; Biomarkers; Anticancer drug response; Anticancer drug toxicity
Categories
Ask authors/readers for more resources
There are an increasing number of studies devoted to the identification of associations between anticancer drug efficacy and toxicity and common polymorphisms present in the patients' genome. However, many articles presenting the results of such studies do not bring the simple and necessary background information allowing the evaluation of the relevance of the study, its significance and its potential importance for patients' treatment. This position paper first addresses clinical oncologists with the aim of giving them the basic knowledge on pharmacogenetics and on the potential use of gene polymorphisms as predictive biomarkers in routine and clinical research. A secondary objective is to give molecular biologists some recommendations on how to conceive protocols and how to publish their results when they develop pharmacogenetic studies appended to clinical trials or with autonomous goals. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available